|Bid||570.05 x 0|
|Ask||0.00 x 0|
|Day's range||559.95 - 572.25|
|52-week range||483.75 - 678.00|
|Beta (3Y monthly)||0.16|
|PE ratio (TTM)||30.13|
|Earnings date||6 Aug 2019 - 10 Aug 2019|
|Forward dividend & yield||3.00 (0.53%)|
|1y target est||N/A|
Drug major Cipla on Tuesday said it has received final approval from the United States Food and Drug Administration (USFDA) for Ambrisentan tablets, indicated for the treatment of pulmonary arterial hypertension.
Drug major Cipla and its subsidiary Cipla USA Wednesday announced a phased launch of generic cinacalcet hydrochloride tablets.
Cipla Ltd, India's second-largest generic drugmaker by market capitalisation, reported on Wednesday a 17.1 percent drop in quarterly profit, dragged down by higher tax expenses and weak sales in domestic ...
Bio-Thera Solutions Ltd announced today that it has reached a licensing agreement with Cipla Limited for BAT1706, its bevacizumab biosimilar, under which Cipla will have exclusive rights to distribute and market the drug in select emerging markets.
The stock fell up to 8.2% to intra day low of 558.10 compared to its previous close of 608.50 on the BSE. The stock has lost 7.44% since the beginning of this year and fallen 12.13% during the last one year.
Cipla Ltd, India's second-largest drugmaker by market capitalisation, warned on Monday of "multiple headwinds" in the second half of the financial year after its quarterly profit fell short of ...
The Ugandan unit of India's pharmaceutical giant Cipla raised 167 billion Ugandan shillings ($43.8 million) from its oversubscribed initial public offering (IPO), an investment bank that helped advise on the transaction said on Monday. Cipla Quality Chemical Industries Ltd (CQCIL), majority owned by India's third-largest drugmaker, sold 657 million shares equivalent to 18 percent of the firm's total equity. Each share in the IPO was priced at 256.5 shillings and closed the first day of trading up 2.1 percent at 262 Ugandan shillings.
A look at the shareholders of Cipla Limited (NSE:CIPLA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...
The Ugandan unit of Indian drugmaker Cipla priced its initial public offering on Tuesday at 256.5 shillings per share, aiming to raise $45 million from its listing on the Kampala stock exchange next month. Cipla Quality Chemical Industries, which is majority owned by India's third-largest drugmaker, is selling 657,179,319 shares, or an 18 percent stake in the company. Chief Executive Officer Emmanuel Katongole, in a statement, said the IPO would enable Ugandan investors to share in the company's success.
Indian drugmaker Cipla Ltd posted quarterly profit well above analysts' expectations, helped by strong growth in the domestic market. Net profit rose 10.4 percent from a year earlier to 4.51 billion rupees ...
Ugandan drugmaker Cipla Quality Chemical Industries Ltd said on Thursday it plans an initial public offering and a listing on the East African country's stock exchange. The company said each of its shareholders would be "selling a minority of their stakes" in the IPO and that the transaction and potential listing had received regulatory approvals. The drug maker, majority-owned by India's pharmaceutical giant Cipla, was established in 2005 and has a manufacturing plant in the Ugandan capital Kampala.
Cipla Limited’s (NSE:CIPLA) announced its latest earnings update in March 2018, which indicated that the company gained from a robust tailwind, leading to a double-digit earnings growth of 40.16%. InvestorsRead More...